Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant
May 03, 2022 06:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 03, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Inc. Announces $14.8 Million Private Placement
March 31, 2022 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update
March 30, 2022 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Schedules 2021 Fiscal Year Business Update Conference Call
March 29, 2022 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 29, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid
January 27, 2022 07:30 ET
|
Orgenesis Inc.
Orgenesis achieves milestone in the placement of the Orgenesis Mobile Processing Units and Lab (OMPUL) for the development of cell and gene therapies at the Hospital OMPULs expected to contribute to...
Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing
January 18, 2022 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs
November 29, 2021 07:00 ET
|
Orgenesis Inc.
JV named a “Priority Investment of Strategic National Importance” by the government of GreeceGranted fast-track licensing and approval status GERMANTOWN, Md., Nov. 29, 2021 (GLOBE NEWSWIRE) --...
Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies
November 15, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year
November 04, 2021 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Schedules Third Quarter 2021 Business Update Conference Call
November 02, 2021 09:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...